ZIHIPP

• 72110 - Research and experimental development on biotechnology

Zihipp Limited, a UK-based biopharmaceutical company focused on the development of peptide hormones for the treatment of diabetes and obesity, announces it has completed a £3.3 million Series A financing round. The investment was led by Mubadala Investment Company, an investment and development company owned by the Government of Abu Dhabi... Zihipp is committed to transforming the lives of patients with diabetes and obesity by developing safe and effective weight loss therapies that deliver the benefits of gastrointestinal surgery without the need to have an operation.

Also known as: Zihipp Limited, ZIHIPP LTD

Registration numbers: 08341001 (CH)

Primary location: London United Kingdom